Iovance Biotherapeutics Inc
NASDAQ:IOVA
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Price:
3.885
USD
2.51%
Market Closed
Market Cap:
$1.5B
Relative Value
The Relative Value of one
IOVA
stock under the Base Case scenario is
11.827
USD.
Compared to the current market price of 3.885 USD,
Iovance Biotherapeutics Inc
is
Undervalued by 67%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IOVA
Relative Value
Base Case
11.827
USD
Undervaluation 67%
Multiples Across Competitors
IOVA Competitors Multiples
Iovance Biotherapeutics Inc Competitors
Iovance Biotherapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
1.6B USD | 5.9 | -4 | -3.5 | -3.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.7B USD | 6.7 | 97.4 | 16 | 22.2 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.4B USD | 5.7 | 27 | 15.4 | 15.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.3B USD | 6.3 | 21.8 | 13.5 | 16.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.9B USD | 10.5 | 31.9 | 24.1 | 25.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 13.7 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
71.1B AUD | 3.2 | 16.7 | 11.5 | 14.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR | 11.4 | 36.5 | 39.7 | 40.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
